Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 611,400 shares, a drop of 39.5% from the November 15th total of 1,010,000 shares. Approximately 4.7% of the shares of the stock are sold short. Based on an average daily volume of 180,400 shares, the days-to-cover ratio is currently 3.4 days.

Institutional Trading of Affimed

Institutional investors and hedge funds have recently bought and sold shares of the business. Choreo LLC acquired a new position in shares of Affimed in the second quarter valued at approximately $54,000. Intellectus Partners LLC grew its stake in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares in the last quarter. FMR LLC increased its position in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Point72 Asset Management L.P. increased its position in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the period. Finally, Jane Street Group LLC purchased a new position in Affimed in the third quarter valued at $44,000. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AFMD. Stifel Nicolaus dropped their price target on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. Wells Fargo & Company dropped their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Affimed in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Affimed currently has an average rating of “Moderate Buy” and an average target price of $13.50.

Affimed Trading Down 3.5 %

Shares of NASDAQ AFMD opened at $2.18 on Friday. Affimed has a 52-week low of $2.02 and a 52-week high of $8.95. The business’s 50 day moving average is $3.10 and its two-hundred day moving average is $4.19. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.